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Recent advances in genome research have enabled the identiﬁcation of new genomic variations that are associated with type 2 diabetes
mellitus (T2DM). Via ﬁne mapping of SNPs in a candidate region of chromosome 21q, the current study identiﬁes potassium inwardly-
rectifying channel, subfamily J, member 15 (KCNJ15) as a new T2DM susceptibility gene. KCNJ15 is expressed in the b cell of the
pancreas, and a synonymous SNP, rs3746876, in exon 4 (C566T) of this gene, with T allele frequency among control subjects of
3.1%, showed a signiﬁcant association with T2DM affecting lean individuals in three independent Japanese sample sets (p¼ 2.53 107,
odds ratio [OR] ¼ 2.54, 95% conﬁdence interval [CI] ¼ 1.76–3.67) and with unstratiﬁed T2DM (p ¼ 6.7 3 106, OR ¼ 1.76, 95%
CI ¼ 1.37–2.25). The diabetes risk allele frequency was, however, very low among Europeans in whom no association between this
variant and T2DM could be shown. Functional analysis in human embryonic kidney 293 cells demonstrated that the risk allele of
the synonymous SNP in exon 4 increased KCNJ15 expression via increased mRNA stability, which resulted in the higher expression
of protein as compared to that of the nonrisk allele.We also showed that KCNJ15 is expressed in human pancreatic b cells. In conclusion,
we demonstrated a signiﬁcant association between a synonymous variant in KCNJ15 and T2DM in lean Japanese patients with T2DM,
suggesting that KCNJ15 is a previously unreported susceptibility gene for T2DM among Asians.Introduction
Type 2 diabetes mellitus (T2DM [MIM 125853]) is recog-
nized as one of the leading health problems throughout
the developed world. There is some evidence that T2DM
is also becoming increasingly common in the developing
countries.1,2 Clinical studies have indicated that T2DM
comprises heterogeneous phenotypes among the various
ethnic groups. During the last 40 years, the prevalence of
T2DM in Japan has increased dramatically, partially due
to the biological implications of genetic risk factors being
exposed to environmental changes including high-calorie
diets and a sedentary lifestyle. Despite the rise in T2DM, it
has been reported that Asian patients are still characterized
by a lower body-mass index (BMI) and lower serum insulin
levels than those in Mexican American or African Amer-
ican T2DM patients.3–5 Numerous studies have also
revealed a striking difference in the average BMI of
T2DM patients among different human populations: The
UK Prospective Diabetes Study (UKPDS) reported a BMI
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the primary sibling-pair set in the current study was
23.053.0 (mean5 standarddeviation [SD]).8 These results
suggest that a lean Asian individual may have some unique
risk susceptibility for developing diabetes mellitus.
We have previously identiﬁed suggestive evidence for
linkage with T2DM in lean individuals (‘‘lean T2DM’’) in
a region of chromosome 21q (ch21q). Upon examination
of 116 T2DM families via affected-sibling-pair analysis,
we showed a LOD score of 2.42.8 Recently, large-scale
genome-wide association studies revealed several genetic
variants to be responsible for T2DM,9–16 though no suscep-
tibility gene on ch21q has been reported to date.
In the current study, we aimed to identify novel suscep-
tibility genes for lean T2DM by follow-up examinations
of our candidate region on ch21q. By applying SNP typing
of this locus, we demonstrate a signiﬁcant association
between potassium inwardly-rectifying channel, subfamily J,
member 15 (KCNJ15) and Asian T2DM. In addition, we
evaluate the functional signiﬁcance of this susceptibility
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Subjects and Methods
Subjects and Genomic DNA
T2DM patients were recruited at the Diabetes Center of Tokyo
Women’s Medical University. The diagnosis of T2DM was made
on the basis of the 1985 World Health Organization criteria.17
We excluded diabetic patients who required insulin therapy
within 2 yrs of diagnosis. Glutamic acid decarboxylase (GAD)-
antibody-positive patients (including those whose ﬁrst-degree
relative was GAD-antibody positive) and patients with maturity-
onset diabetes of the young were also excluded. The clinical
features of the diabetic subjects were obtained by medical inter-
view at the time of blood sampling and inspection of medical
records. The ﬁrst sample set was composed of 149 T2DM cases
for the pooled sample and individual typing, 96 lean cases out
of 149 cases for the pooled sample only, and 200 healthy controls
for the pooled sample, individual typing, and variation screening
(Table S1, available online). The case samples were selected from
the affected sibling pairs used in the previous linkage analysis.8
We assembled two independent subject panels for replication.
Replication A consisted of 419 cases and 500 healthy controls,
and replication B consisted of 1000 cases and 1000 healthy con-
trols. All participants gave written, informed consent, and the
study was approved in advance by the research ethics committees
of the Graduate School of Medicine, The University of Tokyo, and
Tokyo Women’s Medical University. In our previous study, we
made BMI subsets from lean cutoff values of 20, 21, 22, 23, 24,
25, or 27 kg/m2. The LOD score was highest in the leanest family,
whose BMI was less than 24. The purpose of this study was for
following up on the initial study, so we used the same threshold
(BMI 24). A lean case was deﬁned as an individual with a BMI
less than 24 at the time of blood sampling. Lifelong lean cases
were deﬁned as having a maximal BMI below 24 for the follow-
up period. The KCNJ15 rs3746876 variant was genotyped in
9574 Danish individuals, including three different study groups.
One was the group from the Inter99 study (ClinicalTrials.gov ID
no.: NCT00289237), which is a population-based intervention
study for prevention of cardiovascular disorders. In the present
study, a sample of 5784 treatment-naive individuals who had
undergone an oral glucose tolerance test (OGTT) were included
for genetic studies. According to their response to OGTT, the
people could be categorized as subjects with normal glucose toler-
ance (n ¼ 4381), impaired fasting glycemia (n ¼ 489), impaired
glucose tolerance (n ¼ 669), or screen-detected and treatment-
naive type 2 diabetes (n ¼ 245). Another study group was made
up of the type 2 diabetes cases (n ¼ 1658) and glucose-tolerant
control individuals (n¼ 504) ascertained at Steno Diabetes Center.
The ﬁnal study group was made up of screen-detected T2DM
patients from the Danish ADDITION study (ClinicalTrials.gov ID
no.: NCT00237548) (n ¼ 1551). Type 2 diabetes case-control
studies included all healthy glucose-tolerant subjects obtained
from the Inter99 cohort (n ¼ 4381) and ones from Steno Diabetes
Center (n ¼ 504), as well as type 2 diabetes cases obtained from
Steno Diabetes Center (n ¼ 1658), the ADDITION study (n ¼
1551), and the Inter99 study (n ¼ 322; made up of 117 patients
with known type 2 diabetes and 245 with screen-detected type 2
diabetes). Clinical characteristics (mean 5 SD) of the cases are as
follows: age 60.45 9.7 years, BMI 30.75 5.5 kg/m2, HbA1c 7.05
1.6%, age at diagnosis for clinical-onset cases 52.3 5 11.0 yrs.
Clinical characteristics (mean5 SD) of the controls are as follows:
age 46.4 5 8.8 yrs, BMI 25.5 5 4.1 kg/m2. Quantitative associa-The Ation studies of intermediary diabetes-related traits were performed
in the population-based Inter99 cohort, excluding individuals
with previously diagnosed and treated type 2 diabetes. All partic-
ipants provided written informed consent, and the protocol
was approved by the ethics committee of each participating insti-
tution.Estimation of Allele Frequency in Screening
and Genotyping
The estimation of allele frequency for each SNP was performed via
capillary electrophoresis single-strand conformation polymor-
phism (CE-SSCP) analysis as previously reported.18 Pooled DNA
aliquot from each sample was adjusted to a ﬁnal concentration
of 10 ng/ml, as previously described. Primer sequence, annealing
temperature, and SSCP temperature are shown in Table S2. Varia-
tion screening and target polymorphisms in the screening study
were genotyped via direct sequencing (Table S3). In the replication
study, polymorphisms were genotyped via TagMan allelic discrim-
ination (KBiosciences).RNA Isolation and Real-Time PCR from Peripheral
Blood, Cell Line, and Human Langerhans Islet
Total RNA was isolated from peripheral-blood mononuclear cells
(PMNCs) of healthy volunteers with the use of a PAXgene Blood
RNA Kit (QIAGEN). In accordance with instructions from labora-
tory manuals of deoxyribonuclease (100 ng) treatment, oligo
(dT) reverse-transcription reactions were performed. Quantitative
real-time PCR (Q-PCR) was performed with SYBR Green PCR
Master Mix (Applied BioSystems). Normalization of the relative
expression of the genes of interest to the b-actin gene was per-
formed. Q-PCR primer sequences are shown in Table S4.RNA Differential Plot Analysis
RNA differential plot (RDP) analysis was performed as previously
described.19 In brief, the PCR products were labeled with the
ﬂuorescent dye 6-FAM with the use of the speciﬁc primers 50-ATG
ACCTGGTTCCTTTTTGG-30 and 6FAM-50-GGGTTCTAAGTCCCC
ATGAA-30. Capillary electrophoresis was carried out, and the
signal intensity of the polymorphic or mutated fragments was
analyzed with the software program GeneMapper Analysis
(Applied BioSystems). The expression ratio was calculated by
dividing the RNA ratio by the genomic DNA ratio.Immunoﬂuorescence Staining
Human tissue was provided from the Human Tissues & Bioﬂuids
Bank (Asterand). The tissue sample was surgically removed
because of tumor-related pancreas disease. KCNJ15 and insulin
immunoﬂuorescence double staining was carried out with frozen
sections. Frozen sections 5 mm in thickness were cut with cryo-
tome and placed on slides. The frozen sections were then dried
at room temperature and ﬁxed with acetone for 10 min. The slides
were washed with PBS three times and incubated with KCNJ15
antibody overnight and with insulin antibody for 1 hr (Santa
Cruz Biotechnology). After being washed with PBS, the slides
were incubated with Alexa488-conjugated secondary antibody,
for KCNJ15, or with Alexa647-conjugated secondary antibody,
for insulin (Invitrogen), for 40 min. After being washed with
PBS, the sections were visualized with confocal microscopy (LSM
510 Meta NLO Imaging System, Carl Zeiss).merican Journal of Human Genetics 86, 54–64, January 8, 2010 55
RNA-Stability Assay
For evaluation of RNA degradation in the simulated biological
environment, the synthetic RNA from a KCNJ15-cloned vector
was incubated with whole-cell extract. First, we ampliﬁed a PCR
fragment that contained the entire coding region of KCNJ15
from each allele carrier (rs3746876: 566C and 566T) genomic
DNA by using the speciﬁc primers 50- GGGGACAAGTTTGTACAA
AAAAGCAGGCTCTGCCGCCATGGATGCCATTCACATCG-30 and
50- GGGGACCACTTTGTACAAGAAAGCTGGGTCGACATTGCTC
TGTTGTAATAAAAGTGT-30. The ampliﬁed DNA fragments were
inserted into the DONR221 vector and subsequently into the
pcDNA3.1/nV5-DEST (Invitrogen) expression vector. KCNJ15
mRNA was expressed by the T7 promoter without cells and was
puriﬁed according to the manufacturer’s instructions (RiboMax
Large-Scale RNA Production System-T7, Promega). We prepared
whole-cell lysates of HEK 293 cells with extraction buffer (0.5%
Nonidet P-40; 20 mM HEPES buffer, pH 8.0; 20% glycerol [v/v];
400 mM NaCl; 0.5 mM dithiothreitol; 0.2 mM EDTA; and 1%
protease-inhibitor cocktail). Diluted whole-cell extracts (1:500)
were incubated with 5 mg of synthesized RNA at room temperature
for 15 min. The reaction was stopped by the addition of form-
amide dye, and the samples were heated at 68C for 5 min.
RNAs were then detected via electrophoresis on a 2% agarose gel
and stained with DynaMarker RNA Easy Measurement N (Bio-
Dynamics Laboratory). Gels were scanned with a CCD camera
system (LAS-4000mini; Fuji Photo Film), and full-length RNA
intensitywasmeasuredon aDocuCentreColor 500cp (Fuji-Xerox).Immunoblotting and FACS Analysis of Recombinant
KCNJ15 Protein in HEK 293 Cells
We examined the inﬂuence of rs3746876 (C566T) on protein
expression by immunoblotting with membrane fraction and
ﬂuorescence-activated cell sorting (FACS) analysis with the whole
cell. KCNJ15 was cloned into the pcDNA6.2/C-EmGFP-DEST
vector (Invitrogen) and transfected into human embryonic kidney
(HEK) 293T cells with Lipofectamine 2000 (Invitrogen) in 24-well
plates. After 48 hr of incubation, the cells were washed with PBS
(pH 7.4) and permeabilized with radioimmunoprecipitation assay
buffer containing a protease-inhibitor cocktail. The membrane
fraction was collected after centrifuging at 10,000 3 g for 30 min,
resuspended in permeabilization buffer, and solubilized with SDS-
PAGE sample buffer containing 100 mM dithiothreitol and 2%
SDS. To increase mobility, we incubated the membranes in the
same sample buffer for at least 24 hr at room temperature, fol-
lowed by heating at 50C for 15 min, at 20C for 30 min, and at
50C for 15 min, as previously reported for an SDS-resistant
inward rectiﬁer.20 The lysates were separated on a 10%–20%
gradient SDS-polyacrylamide gel. After proteins were transferred
from the gel to a polyvinylidene ﬂuoride membrane (Amersham
Biosciences), Immunoblot analysis was performed with the use
of 1:2000 diluted rabbit polyclonal green ﬂuorescent protein (GFP)
antibody (Medical & Biolocal Laboratories) and 1:100 diluted
rabbit polyclonal E-cadherin antibody (Santa Cruz Biotechnology)
for 1 hr at room temperature. Get Signal (Toyobo) was added to the
antibody-dilution buffer to reduce background. Chemilumines-
cence was detected via ECL Plus (Amersham Biosciences) with
a charge-coupled device (CCD) camera system. For FACS analysis,
GFP fusion-KCNJ15 protein-expressing plasmid-transfected HEK
293 cells were treated with trypsin-EDTA for 5 min at 37C, fol-
lowed by vigorous pipetting to create a single-cell suspension.
Cells were stringently washed and ﬁxed in 2% paraformaldehyde,56 The American Journal of Human Genetics 86, 54–64, January 8, 20and ﬂuorescence derived from GFP was detected by ﬂow cytome-
try (BD LSR-II, BD Biosciences). Flow cytometry was performed
at a 488 nm excitation wavelength and an emission ﬁlter of
535 nm to measure the average signal intensity of each cell. The
transfected cell whose signal intensity was more than that of the
upper limit in negative control was deﬁned as a GFP-positive cell.
Overexpression in Cultured Rat Insulinoma Cell
Cultured rat insulinoma cells (INS1) were transfected with
pcDNA6.2/C-EmGFP-DEST vector-cloned human KCNJ15 or
entry vector, as in previous experiments. Cells were incubated
for 72 hr to allow overexpression of the KCNJ15 gene. Transfected
INS1 were cultured in 24-well plates and preincubated for 30 min
at 37C in glucose-free Krebs-Ringer buffer, followed by 1 hr of
incubation with 5 mM glucose or 25 mM glucose for the determi-
nation of insulin secretion. Insulin secreted into the medium was
measured via ELISA (Rat Insulin ELISA Kit, Mercodia AB).
Statistical Analysis
Data for subjects are presented as mean5 SD or standard error of
the mean [SEM]. Hardy-Weinberg equilibrium was assessed by the
c2 analysis. The overall distribution of alleles was analyzed with
the use of 2 3 2 contingency tables. Statistical signiﬁcance was
deﬁned as p < 0.05. In the pooled-sample analysis, the threshold
of p values was set to 0.05 in order to minimize pseudonegatives.
In genotyping data, a lower p value is presented with dominant or
recessive models. The Danish case-control study was analyzed by
logistic regression adjusted for the effect of age and sex under
the assumption of a multiplicative genetic model. Quantitative
traits in the Inter99 cohort were analyzed by linear regression
adjusted for age, sex, and BMI (when appropriate).
Tag SNPs were selected by estimated haplotype construction
calculated by Haploview 4.1 with Japanese genotype data from
the HapMap project. The haplotype analysis was performed.
Permutation-based hypothesis testing (10,000 permutations) was
performed for the examination of associations of estimated haplo-
type frequencies. We performed permutation tests for correction
of multiple testing by the Haploview permutation function on
all tested markers and haplotypes.Results
Association Mapping in the Candidate Region
on ch21q
We focused on the candidate region contained within the
physical positions between 38,000,000 and 46,944,323 on
ch21q, which also contained the peak LOD-score region
outlined in our previous report (Figure 1A and Table 1). In
theﬁrst screening, a case-control association studywas con-
ducted, involving 149 unrelated T2DM patients derived
from an original sibling-pair set and 200 healthy unrelated
individuals. Ninety-six T2DMpatientswere deﬁned as lean,
given that their BMI was lower than 24 kg/m2 (Table 2).
In order to clarify the primary gene conferring the LOD
score, we selected a total of 86 SNPs in this region. To
estimate the allele frequencies of each SNP, capillary-elec-
trophoresis single-strand conﬁrmation polymorphism
(CE-SSCP) analysis was performed as reported.18 Sixty-
ﬁve SNPs out of 86 were successfully analyzed, and allele10
Figure 1. Association Mapping in the
Ch21q Candidate Region with Pooled
Samples and Variants of KCNJ15 and Their
Association with T2DM
(A) LOD score of linkage analysis on
ch21q.8
(B) Association mapping in the region
between D21S1440 and D21S1446.
(C) KCNJ15 structure and the SNPs de-
tected by variation screening. Black blocks
represent coding regions, and white blocks
represent the untranslated regions. Loca-
tion and frequencies of the KCNJ15 SNP
in case and control samples are shown in
Table 1.frequencies between the cases and the controls were
compared (Table S2). Five SNPs showed nominal signiﬁ-
cant differences on the basis of the estimation by CE-SSCP
analysis (Figure 1B).
Individual genotyping by direct sequencing for these
ﬁve SNPs in the 149 T2DM cases and 200 control subjects
and subsequent association analysis revealed that one SNP
(rs743296 T allele and dominant model [C/T or T/T] geno-
type) showed a signiﬁcant association with unstratiﬁed
T2DM and with lean T2DM (Table S5). The minor T allele
frequency in all T2DM patients was signiﬁcantly lower
than that in controls (24.3% and 31.6%, respectively;
p ¼ 0.042). Moreover, the association with lean T2DM
was more prominent (21.4% and 31.6%, respectively;
p ¼ 0.013). In the genotype comparison, the frequency
of homozygotes for the major allele in patients was signif-
icantly higher than that in controls (61.1% and 44.3%,
respectively; p ¼ 2.73 103). Again, the lean cases showed
more prominent association (67.0% and 44.3%, respec-
tively; p ¼ 4.2 3 104).
The linkage disequilibrium (LD) block containing
rs743296 covers only one gene, KCNJ15, according to
HapMap data of Japanese panels (Figure S1). Both the
upstream and the downstream regions of the gene belong
to the different LD blocks, and the SNPs in the adjacent
genes did not show signiﬁcant association. Thus, KCNJ15
was considered as a primary gene in this candidate region.
Replication and Primary SNP of KCNJ15 in
Association with T2DM
After identifying KCNJ15 as a likely primary gene, we per-
formed high-density association mapping to detect theThe American Journal of Humaprimary SNP in this gene. First, we
performed direct sequencing of all of
the exons and the promoter region
of KCNJ15 in 200 healthy, unrelated
Japanese subjects to screen for varia-
tion. The exon-intron structure was
based on the NCBI Refseq database
build 129 (NM_002243, NM_170736,
and NM_170737) (Figure 1). Via the
variation screening, three SNPs inthe promoter and eight SNPs in the exons were detected.
Among them, ﬁve KCNJ15 SNPs had frequencies of more
than 1% in the controls, and no new polymorphisms
were discovered. Genotyping of 149 T2DM cases and 200
controls was carried out for the ﬁve SNPs by direct
sequencing. The association analysis revealed that the
original SNP (rs743296) and the SNP on exon 4 (rs3746876:
C566T of mRNA position on exon 4, based on
NM_002243, at codon 88 for isoleucine) T allele and domi-
nant model (C/T or T/T) genotype showed signiﬁcant asso-
ciations with lean T2DM (rs743296: allele p ¼ 0.013, odds
ratio [OR] ¼ 1.69, genotype p ¼ 4.2 3 104; rs3746876:
allele p ¼ 7.13 103, OR ¼ 3.25, genotype p ¼ 7.63 103)
(Figure 1C).
For the detection of a possible association with SNP(s) in
intron 2, haplotype and LD analyses were performed in the
200 healthy controls, and after the outcome of these anal-
yses, three tag SNPs were selected: C4724A (rs2836252),
T4782A (rs2000457), and T15950C (rs2836266). Five hap-
lotypes showing estimated frequencies of more than 3% in
the controls were subjected to further association analysis.
No signiﬁcant association was, however, observed for any
of the haplotype (Figure S2).
Next, in order to conﬁrm the observed associations in
the ﬁrst sample set, two SNPs (rs743296 and rs3746876)
were analyzed in two independent sample sets composed
of 419 cases and 500 controls (Japanese replication
sample A [replication A]) or 1000 cases and 1000 controls
(Japanese replication sample B [replication B]). rs3746876
(T allele and dominant model [C/T or T/T] genotype)
showed replicated signiﬁcant association in both rep-
lication sets (replication A: p ¼ 6.5 3 103, OR 1.87;n Genetics 86, 54–64, January 8, 2010 57
Table 1. Location and Frequencies of the KCNJ15 SNP in Case and Control Samples
SNP ID rs2836247 rs13433471 rs743296 rs3746876 rs2230033 rs1064273
Polymorphism G-255T C-212G G16183C Ile88Ile (C566T) Asp98Gly C44635T
Annotation Promoter Promoter Intron 2 Exon 4 Exon 4 Exon 4
Allele Frequency
Risk allele T G G T A T
Lean case: major 137 (72.1%) 134 (69.8%) 143 (78.6%) 180 (93.8%) 131 (68.2%) 149 (81.9%)
Lean case: minor 53 (27.9%) 58 (30.2%) 39 (21.4%) 12 (6.3%) 61 (31.8%) 33 (18.1%)
Control: major 266 (67.2%) 269 (67.3%) 238 (68.4%) 390 (98.0%) 282 (70.5%) 340 (89.0%)
Control: minor 130 (32.8%) 131 (32.8%) 110 (31.6%) 8 (2.0%) 118 (29.5%) 42 (11.0%)
Odds ratio 1.26 1.13 1.69 3.25 1.13 1.79
p value n.s. n.s. 0.013 7.1 3 103 n.s. n.s.
Genotype Frequency
Lean case: M/Ma 50 (64.9%) 56 (55.4%) 61 (67.0%) 85 (88.5%) 42 (43.8%) 64 (85.3%)
Lean case: M/ma 37 (39.8%) 22 (25.6%) 21 (23.1%) 10 (10.4%) 47 (49.0%) 21 (24.4%)
Lean case: m/ma 8 (8.4%) 18 (18.8%) 9 (9.9%) 1 (1.0%) 7 (7.3%) 6 (6.6%)
Control: M/Ma 86 (69.9%) 101 (47.4%) 77 (44.3%) 192 (96.5%) 97 (48.5%) 154 (95.7%)
Control: M/ma 94 (50.8%) 67 (36.0%) 84 (48.3%) 6 (3.0%) 88 (44.0%) 32 (17.1%)
Control: m/ma 18 (9.1%) 32 (16.0%) 13 (7.5%) 1 (0.5%) 15 (7.5%) 5 (2.6%)
p valueb n.s. n.s. 4.2 3 104 7.6 3 103 n.s. n.s.
Variations (rs2836246, rs3746875, rs9963, rs2298331, rs7277497, rs3171454) with MAFs less than 1% were omitted.
a M/M, major homozygote; M/m, heterozygote; m/m, minor homozygote.
b Lower p value observed on the basis of genotype frequencies assessed within a recessive or dominant model.replication B: p ¼ 4.9 3 103, OR 1.58) (Table 2). Subclass
analysis with all of the samples from the ﬁrst and the rep-
lication sets showed that the association of rs3746876
was more prominent in the lean T2DM samples, espe-
cially in the lifelong lean cases whose maximal BMI
was less than 24 (all cases combined: p ¼ 6.7 3 106,
OR ¼ 1.76; lean cases combined: p ¼ 2.9 3 106, OR ¼
1.93; lifelong lean cases combined: p ¼ 2.5 3 107,
OR ¼ 2.54).
In an attempt to replicate the positive association of the
KCNJ15 variant with T2DM among Japanese subjects, we
examined the association of rs3746876 with T2DM in
the Danish population. A total of 3531 patients with
T2DM and 4885 glucose-tolerant subjects were studied.
The minor allele frequencies (MAFs) in the Danish popula-
tion were signiﬁcantly lower as compared to those in the
Japanese population (Danish: controls 0.8%, cases 0.7%;
Japanese: all controls 3.1%, all cases 5.4%). In the simula-
tion study, the sample size of the Danish case-control study
yielded 80% statistical power for detecting association if
the relative risk is larger than 1.5 (Figure S3). However, as
shown in Table 2, there were no signiﬁcant differences in
either allele frequency or genotype frequency of KCNJ15
rs3746876 between T2DM cases and glucose-tolerant indi-
viduals. Also, analysis of T2DM-related quantitative traits
in 5783 participants of the Danish population-based58 The American Journal of Human Genetics 86, 54–64, January 8, 20Inter99 cohort revealed no statistically signiﬁcant associa-
tions (Table 3).TheKCNJ15 rs3746876 (C566T) PolymorphismAffects
mRNA Level
We measured the mRNA level of KCNJ15 extracted from
peripheral-blood cells in 16 healthy volunteers and exam-
ined the association with rs3746876 (C566T) genotypes.
The mRNA level was signiﬁcantly higher in the T/C or
T/T genotype than in the C/C genotype (p ¼ 0.0036)
(Figure 2A). The relative ratio of the allele T mRNA level
to that of the allele C was measured by RDP analysis with
the T/C heterozygote samples.19 The level of the allale
T mRNA was signiﬁcantly higher than that of the allele
C mRNA (Figure 2B).Localization of Kcnj15 in the Pancreas
The reference data from Affymetrix, all exon microarray
data, and the GNF Expression Atlas 1 Human Data on
Affy U95 Chips in the UCSC Genome Browser database
reveal that the expression of Kcnj15 in the pancreas is rela-
tively high, as is that in the kidney, thymus, and whole
blood. The expression of the KCNJ15 molecule in Langer-
hans islets was prominent as compared with that of
exocrine glands in nondiabetic humans (Figure 2C).10
Table 2. Replication Analysis for KCNJ15 rs3746876 (C566T)
Sample
Allele (%) Genotype (%) p Valuea ORa (95% CI)
C T C/C C/T T/T Allele Genotype Allele Genotype
Japanese Population
Screening
sample
Controls 390 (98.0) 8 (2.0) 192 (96.5) 6 (3.0) 1 (0.5) - - - -
All cases 279 (94.3) 17 (5.7) 132 (89.2) 15 (10.1) 1 (0.7) 9.1x103 6.9x103 2.97 (1.26-6.98) 3.32 (1.33-8.30)
Lean cases 180 (93.8) 12 (6.3) 85 (88.5) 10 (10.4) 1 (1.0) 7.1x103 7.6x103 3.25 (1.31-8.09) 3.55 (1.33-9.47)
Lifelong
lean cases
67 (93.1) 5 (6.9) 32 (88.9) 3 (8.3) 1 (2.8) 0.019 0.047 3.63 (1.16-11.46) 3.43 (0.95-12.38)
Replication
sample A
Controls 963 (96.5) 35 (3.5) 465 (93.2) 33 (6.6) 1 (0.2) - - - -
All cases 768 (93.7) 52 (6.3) 360 (87.8) 48 (11.7) 2 (0.5) 6.5x103 5.3x103 1.87 (1.20-2.89) 1.90 (1.20-3.00)
Lean cases 481 (93.2) 35 (6.8) 225 (87.2) 31 (12.0) 2 (0.8) 4.0x103 6.1x103 2.00 (1.24-3.24) 2.01 (1.21-3.32)
Lifelong
lean cases
176 (90.7) 18 (9.3) 81 (83.5) 14 (14.4) 2 (2.1) 3.5x104 1.6x103 2.84 (1.56-5.08) 2.70 (1.43-5.12)
Replication
sample B
Controls 1,937 (96.9) 63 (3.2) 937 (93.7) 63 (6.3) 0 (0.0) - - - -
All cases 1,902 (95.1) 98 (4.9) 906 (90.6) 90 (9.0) 4 (0.4) 4.9x103 0.01 1.58 (1.14-2.19) 1.54 (1.11-2.15)
Lean cases 966 (94.7) 54 (5.3) 458 (89.8) 50 (9.8) 2 (0.4) 3.9x103 6.9x103 1.72 (1.19-2.49) 1.69 (1.15-2.48)
Lifelong
lean cases
282 (93.4) 20 (6.6) 131 (86.8) 20 (13.2) 0 (0.0) 2.6x103 2.1x103 2.18 (1.30-3.66) 2.27 (1.33-3.88)
Combined
samples
Controls 3,290 (96.9) 106 (3.1) 1,594 (93.9) 102 (6.0) 2 (0.1) - - - -
All cases 2,949 (94.6) 167 (5.4) 1,398 (89.7) 153 (9.8) 7 (0.4) 6.7x106 1.5x105 1.76 (1.37-2.25) 1.75 (1.36-2.27)
Lean cases 1,627 (94.2) 101 (5.8) 768 (88.9) 91 (10.5) 5 (0.6) 2.9x106 8.7x106 1.93 (1.46-2.55) 1.92 (1.43-2.56)
Lifelong
lean cases 525 (92.4) 43 (7.6) 244 (85.9) 37 (13.0) 3 (1.1) 2.5x107 1.7x106 2.54 (1.76-3.67) 2.51 (1.70-3.71)
Danish Population
Controls 9694 (99.2) 76 (0.8) 4,809 (98.4) 76 (1.6) 0 (0.0) - - - -
All cases 7013 (99.3) 49 (0.7) 3482 (98.6) 49 (1.4) 0 (0.0) 0.53 0.53 0.89 (0.62-1.28) 0.89 (0.62-1.28)
Lean cases 3470 (99.3) 26 (0.7) 1722 (98.5) 26 (1.5) 0 (0.0) 0.84 0.84 0.96 (0.61-1.50) 0.96 (0.61-1.50)
Lifelong
lean cases
903 (99.4) 5 (0.6) 449 (98.9) 5 (1.1) 0 (0.0) 0.45 0.45 0.70 (0.28-1.75) 0.70 (0.28-1.75)
A Japanese lean case was defined as one with a BMI % 24 at the time of sampling.
A Japanese lifelong lean case was defined as one with a lifelong BMI % 24.
A Danish relative lean case was defined as one with a BMI % 30.0; the 50th percentile of T2DM cases.
A Danish absolute lean case was defined as one with a BMI % 25.0; the 50th percentile of population-based control samples.
a As compared with control.Association of the rs3746876 (C566T) Polymorphism
with Insulin Deﬁciency andMaximal BMI in Japanese
T2DM Patients
We analyzed potential associations between genotypes
and BMI, estimates of insulin secretion and resistance,
age at diagnosis, and response to therapeutic intervention.
The maximal BMI of patients with the T/T genotype was
signiﬁcantly lower than that of those with the C/C or the
C/T genotype (p ¼ 0.046) (Figure 3A). Moreover, the prev-
alence of patients who required insulin therapy during the
follow-up study was signiﬁcantly higher in the patients
with the T/C or T/T genotype than in those with the C/CThe Agenotype (p ¼ 0.047) (Figure 3B). The age at diagnosis
and estimates of insulin secretion and insulin resistance,
calculated by the HOMA-IR,21 did not associate with
rs3746876 (Figure 3C).
In Vitro Functional Analysis of the rs3746876 (C566T)
Polymorphism
The stability of the mRNA was then analyzed as previously
described.22 Synthetic KCNJ15 mRNA carrying the T allele
was degraded at a signiﬁcantly reduced rate as compared to
that carrying the C allele (p ¼ 0.039) (Figure 4A). These
data indicated that the T allele carrier individuals maymerican Journal of Human Genetics 86, 54–64, January 8, 2010 59
Table 3. Quantitative Intermediary Diabetes-Related Traits in Treatment-Naive Individuals from the Population-Based Inter99 Cohort
Stratified with Regard to Genotype of KCNJ15 rs3746876
C/C C/T T/T p Value
N (men/women) 5690 (2824/2866) 93 (46/47) 0
Age (yrs) 46.2 5 7.9 44.7 5 8.1
BMI 26.2 5 4.6 25.6 5 3.7 0.4
Fasting glucose (mmol/l) 5.5 5 0.8 5.4 5 0.5 0.6
Glucose at 30 min (mmol/l) 8.7 5 1.9 8.4 5 1.8 0.3
Glucose at 120 min (mmol/l) 6.2 5 2.1 6.2 5 2.1 0.7
Incremental AUC for glucose 2215 136 2115 140 0.8
Fasting insulin (pmol/l) 35 (24–52) 35 (26.5–56) 0.1
Insulin at 30 min (pmol/l) 247 (177–357) 220 (160–346) 0.3
Insulin at 120 min (pmol/l) 157 (97–258) 172 (122–237) 0.7
Incremental AUC for insulin 18,810 (13,130–27,420) 17,750 (12,240–24,990) 0.8
Derived Estimates of Insulin Response
Insulinogenic index 24.5 (16.9–36.4) 22.6 (14.6–33.8) 0.2
BIGTT-AIR 1620 (1280–2080) 1580 (1340–2100) 0.8
CIR 651 (400–1061) 634 (369–1229) 0.6
Derived Estimates of Insulin Sensitivity
HOMA-IR (mg/dl 3 mU/ml) 4.8 5 5.5 4.2 5 2.5 0.2
BIGTT-Si 9.2 5 4.1 9.2 5 4.0 0.8
Data are mean 5 SD or median (interquantile range). Values of s-insulin, insulinogenic index, BIGTT-AIR, CIR, and HOMA-IR were logarithmically transformed
before statistical analysis. Calculated p values were adjusted for age, sex, and BMI, except for BMI (age and sex) and BIGTT-AIR and BIGTT-Si (age).
Insulinogenic index: (insulin at 30 min (pmol/l)  fasting insulin (pmol/l)) / glucose at 30 min (mmol/l).
CIR: insulin at 30 min / (glucose at 30 min 3 (glucose at 30 min – 3.89)) 3 100.
HOMA-IR (mU/ml 3 mg/dl): fasting insulin (mU/ml) 3 fasting glucose (mg/dl) / 405.
BIGTT-insulin sensitivity index (BIGTT-Si) and BIGTT-AIR use information about sex and BMI combined with analysis of glucose and insulin levels at the time points
0, 30, and 120 min to provide indices for Si and AIR, which highly correlate with indexes obtained during an intravenous glucose tolerance test, and were calcu-
lated as described elsewhere.36show higher levels of KCNJ15mRNA because of the advan-
tage of its increased stability. Finally, protein expression
levels of KCNJ15 were examined with the use of KCNJ15-
GFP fusion protein expressed in HEK 293 cells. Protein
expression of KCNJ15 was higher in the rs3746876
(T allele) than in rs3746876 (C allele) samples in both the
membrane fraction (p ¼ 0.028) (Figure 4B) and whole-
cell fractions (p ¼ 0.00023) (Figure 4C). For functional
analysis of the protein level of KCNJ15, overexpression
experiments of KCNJ15 were conducted (Figure 4D). Over-
expression of KCNJ15 decreased insulin secretion at high-
glucose conditions (p ¼ 0.035). However, no signiﬁcant
change was found under normoglycemic conditions
(5 mM glucose).Discussion
Applying genome-wide linkage analysis and SNP-based
ﬁne mapping in the candidate region on ch21q, we have
identiﬁed KCNJ15 as a T2DM susceptibility gene in the
Japanese population. We showed that KCNJ15 is expressed60 The American Journal of Human Genetics 86, 54–64, January 8, 20in the b cell of the human pancreas, and functional anal-
ysis revealed that the rs3746876 (C566T) variant in exon
4 potentially affects b cell function.
The ﬁrst peak LOD score of this candidate region on
ch21q, derived from linkage analysis in 164 T2DM families
(256 affected sibling pairs), increased when the linkage
study was limited to the 116 families with lean T2DM
(BMI < 24 kg/m2).8 We started with a case-control associa-
tion study of the unrelated T2DM patients in the original
sample set and healthy control subjects. Estimation of
allele frequency by CE-SSCP18 detected a signiﬁcant associ-
ation of one SNP (rs743296) located in KCNJ15. High-
density mapping in KCNJ15, LD, and haplotype analysis
enabled us to identify rs3746876 (C566T) as the lead SNP
in the region. Moreover, we conﬁrmed the association of
this SNP by two independent replication studies in the
Japanese population. Because there were limitations con-
cerning SNP density and estimation of allele frequencies
with the use of pooled samples, we cannot rule out the
possibility of susceptibility gene(s) other than KCNJ15. In
addition, because of the low frequency of the risk allele
at rs3746876, this SNP alone could not explain the positive10
Figure 2. Genotype andmRNA Level and Local-
ization of KCNJ15
(A) The mRNA expression level of KCNJ15 in
PMNCs from healthy individuals with different
genotypes (eight C/C, seven C/T, and one T/T)
relative to b-actin measured by Q-PCR. Hori-
zontal bars represent mean and SD.
(B) RDP analysis of KCNJ15 in PBMCs from
healthy individuals. Fragments of 66 bp contain-
ing the C allele or the T allele were analyzed:
T and C indicate minor (susceptible) and major
allele fragments, respectively. Average expression
ratios with SD in four independent experiments
are indicated.
(C) Immunoﬂuorescence staining of Kcnj15 and
insulin. A tissue with immunoﬂuorescence stain-
ing was visualized with confocal microscopy.
Kcnj15 was detected as alexa-488 ﬂuorescence
(Kcnj15-green) and insulin by alexa-633 ﬂuores-
cence (insulin-red). The same sections were
merged into the overlapped images (merge).
Human pancreas tissue was a frozen section
from a nondiabetic and surgical operation.linkage result for the chromosomal region. Other variants
located in this region are likely to be present.
It is noteworthy that population-diversity data of
rs3746876 (C566T) are not available from the NCBI data-
base at the time of this study. However, the data are nowFigure 3. Clinical Characteristics Associated with rs3746876
(C566T)
(A) Association of the SNP with BMI of the patients at the time of
diagnosis and maximal BMI throughout the follow-up period.
Values represent mean5 SD.
(B) Association of the SNP with the percentage of patients who
progressed to insulin deﬁciency (required insulin therapy or
HOMA-b less than 10) among the patients who have been fol-
lowed up for more than 10 yrs after diagnosis with each genotype.
(C) Association of the SNP with the percentage of patients who
progress to high insulin resistance (HOMA-IR more than 2 or
more than 4) among patients who have been followed up for
more than 10 yrs after diagnosis with each genotype.
The Aavailable at the HapMmap database. Moreover, as for the
latest genome-wide SNP-typing arrays, only the Human
1M DNA Analysis Beadchip (Illumina) contains this SNP.
The other commercially available platforms, including
the 500K Chip (Affymetrix), the Genome-Wide Human
SNP Array 6.0 (Affymetrix), and the 317K Chip (Illumina),
do not contain this SNP.
Interestingly, the primary diabetes-associated SNP,
rs3746876 (C566T), exhibits a marked difference in allele
frequency between individuals of Japanese and European
ethnicity. For instance, the MAF of the SNP in the general
Danish population was only 0.81%, as opposed to 3.1% in
Japanese control subjects. Therefore, in the Danish geno-
type-phenotype correlation study using 5783 subjects
with T2DM, the number of subjects with a T risk allele
was only 93 (1.1%), whereas the remaining 98.9% individ-
uals were C/C homozygous. No T/T-homozygous individ-
uals were detected in the Danish sample. Thus, this SNP
showed a striking population diversity between European
and Japanese individuals. Statistical power for quantitative
traits in the Inter99 cohort was calculated as previously re-
ported.23 Assuming an allele frequency of 0.0081 and an
additive genetic model, we had 80% statistical power for
detecting an allele-dependent difference of 28% of an SD
at a 5% signiﬁcance level, corresponding to a 12% differ-
ence in BIGTT-acute insulin response (BIGTT-AIR), 21%
in CIR, and 18% in HOMA-IR.
In addition, the clinical data at enrollment were not
associated with genotypes (Table S6). However, it should
be noted that the spectrum of BMI was quite different
from that in the Japanese population (Table S1). Asians,
unlike those of European descent, tend to become diabetic
without being obese. Therefore, it is reasonable to assume
that the genes responsible for Asian diabetes tend to be
concentrated in the subgroup of which the patients aremerican Journal of Human Genetics 86, 54–64, January 8, 2010 61
Figure 4. Functional Analysis of the rs3746876
Polymorphism
(A) Stability of susceptible and nonsusceptible
KCNJ15 transcripts. Values represent mean 5
SEM of data from three independent experi-
ments.
(B) GFP fusion protein expression of KCNJ15 in
the membrane fraction. Immunoblotting anal-
ysis was conducted with the use of GFP antibody.
Values represent mean5 SEM of data from three
independent experiments.
(C) GFP fusion protein expression of KCNJ15 in
whole-cell fractions. The values were measured
by FACS analysis. Values represent mean5 SEM
of data from three independent experiments.
(D) INS-1 cells were cultured for 72 hr, and
insulin secretion was determined after a 1 hr
incubation in 5 mM or 25 mM glucose. Results
are expressed as a percentage of 5 mM glucose.
Control values: 0.98 5 0.04 mg/mg of protein.
Values represent mean5 SEM.diabetic but not obese. We therefore conducted association
studies in subgroups of the diabetes patients who are lean.
In Japanese participants, the association with T2DM was
more signiﬁcant at lower BMI levels. However, we failed
to ﬁnd such association between the 50th percentile of
lean cases and controls among the Danish participants.
Of interest, variation in KCNQ1 was originally found to
be associated with T2DM in the Japanese population,
and the association was replicated in other ethnicities,
including the Danish population.16,24 The relative risk of
T2DM in carriers of the KCNJ15 risk allele was 1.76, which
increased to 2.54 when the analyses were limited to the
subjects with a BMI less than 24 kg/m2. The ORs estimated
in the present manuscript may be overestimates and
should be validated in later studies. However, these
estimated risk increments are large, suggesting that
rs3746876 (C566T) in the KCNJ15 gene is also an impor-
tant contributor to T2DM susceptibility in the Asian pop-
ulation, as it is in the KCNQ1 gene.
A recent review of the functional properties of synony-
mous SNPs in exons suggested that synonymous SNPs
may inﬂuence gene variant splicing, miRNA, protein
folding and mRNA folding.25 It has also been reported that
SNPs in the 30 untranslated region (UTR) of genesmay affect
the stability of transcripts.26–28 In the present study we
provide evidence that the synonymous SNP (Ile88Ile)
variant inﬂuences mRNA levels and their stability; also the
KCNJ15 protein levels were higher in the T allele carriers
than in non-carriers. The stability of transcripts is suggested
to be regulated by miRNA and/or mRNA folding. Here we
demonstrate changes of the mRNA second structure of
KCNJ15 as predicted by MFOLD software29 (Figure S4).
The KCNJ15 protein is a member of the inwardly-recti-
fying potassium channel (KIR) family and was cloned from
human kidney by Shuck et al.30 According to the initial62 The American Journal of Human Genetics 86, 54–64, January 8, 20channel nomenclature, KCNJ15 was also termed IRKK,
KIR1.3, or KIR4.2. KCNJ15 is abundantly expressed in
many organs, including the pancreas and peripheral blood
mononuclear cells. In the current study, we demonstrated
that a genetically determined increased expression of
KCNJ15 confers susceptibility to T2DM among Japanese,
as well as earlier dependency on insulin treatment in
patients with established T2DM.
On the basis of current knowledge about the functions
of the KiR protein family and the present ﬁndings, we
suggest that KCNJ15 may negatively regulate insulin secre-
tion by maintaining resting membrane potential of
pancreatic b cells and thereby inhibit depolarization, like
KCNJ11.31,32 Recently, the Ca2þ-sensing receptor (CsR)
was demonstrated as the key molecule for a full insulin-
secretory response of b cells,33–35 and, importantly,
KCNJ15 and CsR are functionally associated with each
other, whereas KCNJ11 and CsR are not associated with
each other.35
In conclusion, genome-wide linkage analysis and SNP
ﬁne mapping in the candidate of ch21q have identiﬁed
a new T2DM susceptibility gene, KCNJ15, a molecule asso-
ciated with altered insulin release that may be applicable as
a new therapeutic target in T2DM.Supplemental Data
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